ישראל - עברית - Ministry of Health

rafa laboratories ltd - hyperici herba extractum siccum - טבליות מצופות פילם - hyperici herba extractum siccum 250 mg - other antidepressants - symptoms of mild to moderate depression including: dejected mood, mood lability, inner restlessness, anxiety, states of tension and the difficulty in falling asleep and sleeping through the night which is associated with these conditions. treatment is recommended for up to 12 weeks.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - hyperici herba extractum siccum - טבליות מצופות פילם - hyperici herba extractum siccum 500 mg - other antidepressants - symptoms of mild to moderate depression including: dejected mood, mood lability, inner restlessness, anxiety, states of tension and the difficulty in falling asleep and sleeping through the night which is associated with these conditions.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - hyperici herba extractum siccum - טבליות מצופות פילם - hyperici herba extractum siccum 250 mg

ישראל - עברית - Ministry of Health

rafa laboratories ltd - hyperici herba extractum siccum - טבליות מצופות פילם - hyperici herba extractum siccum 500 mg

ישראל - עברית - Ministry of Health

bayer israel ltd - hypericum perforatum - טבליות מצופות פילם - hypericum perforatum 612 mg - symptoms of mild to moderate depression. treatment is recommended for up to 12 weeks.

ישראל - עברית - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 25 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.